Early Alterations of AMPA Receptors Mediate Synaptic Potentiation Induced by Neonatal Seizures

Department of Neurology, Division of Neuroscience, Children's Hospital, Boston, Massachusetts 02115, USA.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.34). 09/2008; 28(32):7979-90. DOI: 10.1523/JNEUROSCI.1734-08.2008
Source: PubMed


The highest incidence of seizures during lifetime is found in the neonatal period and neonatal seizures lead to a propensity for epilepsy and long-term cognitive deficits. Here, we identify potential mechanisms that elucidate a critical role for AMPA receptors (AMPARs) in epileptogenesis during this critical period in the developing brain. In a rodent model of neonatal seizures, we have shown previously that administration of antagonists of the AMPARs during the 48 h after seizures prevents long-term increases in seizure susceptibility and seizure-induced neuronal injury. Hypoxia-induced seizures in postnatal day 10 rats induce rapid and reversible alterations in AMPAR signaling resembling changes implicated previously in models of synaptic potentiation in vitro. Hippocampal slices removed after hypoxic seizures exhibited potentiation of AMPAR-mediated synaptic currents, including an increase in the amplitude and frequency of spontaneous and miniature EPSCs as well as increased synaptic potency. This increased excitability was temporally associated with a rapid increase in phosphorylation at GluR1 S845/S831 and GluR2 S880 sites and increased activity of the protein kinases CaMKII (calcium/calmodulin-dependent protein kinase II), PKA, and PKC, which mediate the phosphorylation of these AMPAR subunits. Postseizure administration of AMPAR antagonists NBQX (2,3-dihydroxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline), topiramate, or GYKI-53773 [(1)-1-(4-aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine] attenuated the AMPAR potentiation, phosphorylation, and kinase activation and prevented the concurrent increase in in vivo seizure susceptibility. Thus, the potentiation of AMPAR-containing synapses is a reversible, early step in epileptogenesis that offers a novel therapeutic target in the highly seizure-prone developing brain.

Download full-text


Available from: Nikolaus Josef Sucher,
  • Source
    • "What constitutes a complete ASD phenotype in the rodent (Yang et al., 2011)? Are the mechanisms of initiation (Rakhade et al., 2008, 2012; Zhou et al., 2011) and maintenance of ASD/ID similar? What is the role of SRS? Are certain strains genetically predisposed to be susceptible to long term consequences following ELS? "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent work in Exp Neurol by Lugo et al. (2014b) demonstrated chronic alterations in sociability, learning and memory following multiple early life seizures (ELSs) in a mouse model. This work adds to the growing body of evidence supporting the detrimental nature of ELSs on the developing brain to contribute to aspects of an autistic phenotype with intellectual disability. Review of the face validity of behavioral testing and the construct validity of the models used informs the predictive ability and thus the utility of these models to translate underlying molecular and cellular mechanisms into future human studies.
    Experimental Neurology 10/2014; 263. DOI:10.1016/j.expneurol.2014.09.018 · 4.70 Impact Factor
  • Source
    • "A potentially promising therapeutic target to prevent epileptogenesis is the AMPA-type glutamate receptor (AMPAR). In a rat model of neonatal seizures, intraperitoneal administration of AMPAR antagonists within 48 hours of early-life seizures reduced later-life seizure susceptibility and hippocampal neural injury.29 Administration of AMPAR antagonists after seizures reduced kinase activity and phosphorylation of AMPAR subunits, thereby preventing an increase in seizure susceptibility.30 Therefore, changes in AMPAR phosphorylation seem important for epileptogenesis and antagonism of these changes may have antiepileptogenic effects.31 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca(2+) and selectively blocks AMPA receptor-mediated synaptic transmission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.
    Therapeutics and Clinical Risk Management 07/2013; 9(1):285-93. DOI:10.2147/TCRM.S37317 · 1.47 Impact Factor
  • Source
    • "The results are expressed as the mean ± SE (n C 4 per group). Data were analyzed using t-tests, and significance was set at p \ 0.05 Neuromol Med using PILO, kainate, and LiCl-PILO drugs (Bracey et al. 2009; Condorelli et al. 1994; de Oliveira et al. 2011), or prolonged electrical stimulation or hypoxia-inductive SE (Brandt et al. 2003; Rakhade et al. 2008). In addition, the variable drug concentrations utilized or the different experimental time points used following the induction of SE should be taken into account. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glutamate over-activation and the consequent neuronal excitotoxicity have been identified as crucial players in brain dysfunctions such as status epilepticus (SE). Owing to the central function of 2-amino-3-(hydroxyl-5-methylisoxazole-4-yl) propionic acid receptors (AMPARs) in fast excitatory neurotransmission, these receptors have been recognized to play a prominent role in the development and generation of epileptic seizure. This study was undertaken to investigate both the early changes that affect glutamatergic neurons in the rat cerebral cortex and hippocampus and the level and channel properties of AMPARs in response to SE. The results obtained after 3 h of pilocarpine (PILO)-induced SE showed a disorganization of glutamatergic neurons in the CA3 and a thinner neuronal cell layer in the dentate gyrus (DG) region as compared with controls. A significant increase in AMPAR GluA2 protein expression, a decrease in GluA1, GluA3, and GluA4 expression, and a reduction in the phosphorylation of Ser831-GluA1 and Ser880-GluA2 were also observed. In addition, we report a downregulation of R/G editing levels and of Flip splicing isoforms, with a prominent effect on the hippocampus of PILO-treated rats. Our results suggest the presence of an attenuation of AMPARs' post-synaptic excitatory response to glutamate after PILO treatment, thus conferring neuronal protection from the excitotoxic conditions observed in the SE. This study suggests a role for AMPARs in alterations of the glutamatergic pathway during the onset and early progression of epilepsy, thus indicating additional targets for potential therapeutic interventions.
    NeuroMolecular Medicine 03/2013; 15(2). DOI:10.1007/s12017-013-8221-6 · 3.68 Impact Factor
Show more